Perspective Therapeutics (NYSEAMERICAN:CATX) Rating Increased to Strong-Buy at BMO Capital Markets

Perspective Therapeutics (NYSEAMERICAN:CATX) was upgraded by analysts at BMO Capital Markets to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

Several other research firms also recently issued reports on CATX. Bank of America dropped their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Piper Sandler reduced their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has a consensus rating of “Buy” and an average price target of $11.50.

Perspective Therapeutics Stock Up 8.4%

Perspective Therapeutics stock opened at $3.48 on Tuesday. The business has a 50 day moving average of $3.10 and a 200-day moving average of $3.95. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. On average, sell-side analysts anticipate that Perspective Therapeutics will post -1.03 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AXQ Capital LP lifted its position in shares of Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock worth $35,000 after purchasing an additional 2,481 shares during the period. Deutsche Bank AG boosted its stake in shares of Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after purchasing an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. increased its position in shares of Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $69,000 after buying an additional 5,000 shares during the period. Russell Investments Group Ltd. increased its position in shares of Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the period. Finally, Wealth Effects LLC raised its stake in Perspective Therapeutics by 32.0% during the first quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock worth $138,000 after buying an additional 8,000 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.